Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections
Identifieur interne : 002F25 ( Istex/Corpus ); précédent : 002F24; suivant : 002F26Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections
Auteurs : Jordan Dubow ; Angela Kim ; Jerrold Leikin ; Kirk Cumpston ; Sean Bryant ; Michael RezakSource :
- Movement Disorders [ 0885-3185 ] ; 2005-07.
English descriptors
Abstract
Botulinum toxin type B (BTX‐B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX‐A) it has off‐label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX‐B has also been shown to be a safe and effective alternative for patients who are resistant to BTX‐A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX‐B use. In this study, we report on three individual patients who received BTX‐B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX‐B at remote sites. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20466
Links to Exploration step
ISTEX:59E2F4877B7977C1F915CA55E7AB648C4D0EB058Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title><author><name sortKey="Dubow, Jordan" sort="Dubow, Jordan" uniqKey="Dubow J" first="Jordan" last="Dubow">Jordan Dubow</name><affiliation><mods:affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Kim, Angela" sort="Kim, Angela" uniqKey="Kim A" first="Angela" last="Kim">Angela Kim</name><affiliation><mods:affiliation>Department of Plastic Surgery, Section of Ophthalmology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Leikin, Jerrold" sort="Leikin, Jerrold" uniqKey="Leikin J" first="Jerrold" last="Leikin">Jerrold Leikin</name><affiliation><mods:affiliation>Omega, Evanston Northwestern Healthcare, Evanston, and University of Illinois at Chicago and Cook County Hospital, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Cumpston, Kirk" sort="Cumpston, Kirk" uniqKey="Cumpston K" first="Kirk" last="Cumpston">Kirk Cumpston</name><affiliation><mods:affiliation>Department of Emergency Medicine, University of New Mexico and New Mexico Poison Center, Albuquerque, New Mexico, USA</mods:affiliation></affiliation></author><author><name sortKey="Bryant, Sean" sort="Bryant, Sean" uniqKey="Bryant S" first="Sean" last="Bryant">Sean Bryant</name><affiliation><mods:affiliation>Department of Emergency Medicine, Cook County Hospital, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Rezak, Michael" sort="Rezak, Michael" uniqKey="Rezak M" first="Michael" last="Rezak">Michael Rezak</name><affiliation><mods:affiliation>Department of Neurology, Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:59E2F4877B7977C1F915CA55E7AB648C4D0EB058</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20466</idno><idno type="url">https://api.istex.fr/document/59E2F4877B7977C1F915CA55E7AB648C4D0EB058/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title><author><name sortKey="Dubow, Jordan" sort="Dubow, Jordan" uniqKey="Dubow J" first="Jordan" last="Dubow">Jordan Dubow</name><affiliation><mods:affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Kim, Angela" sort="Kim, Angela" uniqKey="Kim A" first="Angela" last="Kim">Angela Kim</name><affiliation><mods:affiliation>Department of Plastic Surgery, Section of Ophthalmology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Leikin, Jerrold" sort="Leikin, Jerrold" uniqKey="Leikin J" first="Jerrold" last="Leikin">Jerrold Leikin</name><affiliation><mods:affiliation>Omega, Evanston Northwestern Healthcare, Evanston, and University of Illinois at Chicago and Cook County Hospital, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Cumpston, Kirk" sort="Cumpston, Kirk" uniqKey="Cumpston K" first="Kirk" last="Cumpston">Kirk Cumpston</name><affiliation><mods:affiliation>Department of Emergency Medicine, University of New Mexico and New Mexico Poison Center, Albuquerque, New Mexico, USA</mods:affiliation></affiliation></author><author><name sortKey="Bryant, Sean" sort="Bryant, Sean" uniqKey="Bryant S" first="Sean" last="Bryant">Sean Bryant</name><affiliation><mods:affiliation>Department of Emergency Medicine, Cook County Hospital, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Rezak, Michael" sort="Rezak, Michael" uniqKey="Rezak M" first="Michael" last="Rezak">Michael Rezak</name><affiliation><mods:affiliation>Department of Neurology, Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-07">2005-07</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="877">877</biblScope><biblScope unit="page" to="880">880</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">59E2F4877B7977C1F915CA55E7AB648C4D0EB058</idno><idno type="DOI">10.1002/mds.20466</idno><idno type="ArticleID">MDS20466</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>parasympathetic dysfunction</term><term>side effects of botulinum toxin B</term><term>visual system disturbance</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Botulinum toxin type B (BTX‐B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX‐A) it has off‐label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX‐B has also been shown to be a safe and effective alternative for patients who are resistant to BTX‐A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX‐B use. In this study, we report on three individual patients who received BTX‐B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX‐B at remote sites. © 2005 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Jordan Dubow MD</name><affiliations><json:string>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Angela Kim MD</name><affiliations><json:string>Department of Plastic Surgery, Section of Ophthalmology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA</json:string></affiliations></json:item><json:item><name>Jerrold Leikin MD</name><affiliations><json:string>Omega, Evanston Northwestern Healthcare, Evanston, and University of Illinois at Chicago and Cook County Hospital, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Kirk Cumpston DO</name><affiliations><json:string>Department of Emergency Medicine, University of New Mexico and New Mexico Poison Center, Albuquerque, New Mexico, USA</json:string></affiliations></json:item><json:item><name>Sean Bryant MD</name><affiliations><json:string>Department of Emergency Medicine, Cook County Hospital, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Michael Rezak MD, PhD</name><affiliations><json:string>Department of Neurology, Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>side effects of botulinum toxin B</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>parasympathetic dysfunction</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>visual system disturbance</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Botulinum toxin type B (BTX‐B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX‐A) it has off‐label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX‐B has also been shown to be a safe and effective alternative for patients who are resistant to BTX‐A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX‐B use. In this study, we report on three individual patients who received BTX‐B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX‐B at remote sites. © 2005 Movement Disorder Society</abstract><qualityIndicators><score>4.057</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>767</abstractCharCount><pdfWordCount>2617</pdfWordCount><pdfCharCount>17192</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>120</abstractWordCount></qualityIndicators><title>Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title><genre><json:string>Serial article</json:string></genre><host><volume>20</volume><pages><total>3</total><last>880</last><first>877</first></pages><issn><json:string>0885-3185</json:string></issn><issue>7</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/mds.20466</json:string></doi><id>59E2F4877B7977C1F915CA55E7AB648C4D0EB058</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/59E2F4877B7977C1F915CA55E7AB648C4D0EB058/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/59E2F4877B7977C1F915CA55E7AB648C4D0EB058/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/59E2F4877B7977C1F915CA55E7AB648C4D0EB058/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2005</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title><author><persName><forename type="first">Jordan</forename><surname>Dubow</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Angela</forename><surname>Kim</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Plastic Surgery, Section of Ophthalmology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA</affiliation></author><author><persName><forename type="first">Jerrold</forename><surname>Leikin</surname><roleName type="degree">MD</roleName></persName><affiliation>Omega, Evanston Northwestern Healthcare, Evanston, and University of Illinois at Chicago and Cook County Hospital, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Kirk</forename><surname>Cumpston</surname><roleName type="degree">DO</roleName></persName><affiliation>Department of Emergency Medicine, University of New Mexico and New Mexico Poison Center, Albuquerque, New Mexico, USA</affiliation></author><author><persName><forename type="first">Sean</forename><surname>Bryant</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Emergency Medicine, Cook County Hospital, Chicago, Illinois, USA</affiliation></author><author><persName><forename type="first">Michael</forename><surname>Rezak</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Movement Disorders Center, Department of Neurology, Glenbrook Hospital, Evanston Northwestern Healthcare, 2100 Pfingsten Road, Suite B110, Glenview, IL 60025</p></note><affiliation>Department of Neurology, Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-07"></date><biblScope unit="vol">20</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="877">877</biblScope><biblScope unit="page" to="880">880</biblScope></imprint></monogr><idno type="istex">59E2F4877B7977C1F915CA55E7AB648C4D0EB058</idno><idno type="DOI">10.1002/mds.20466</idno><idno type="ArticleID">MDS20466</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Botulinum toxin type B (BTX‐B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX‐A) it has off‐label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX‐B has also been shown to be a safe and effective alternative for patients who are resistant to BTX‐A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX‐B use. In this study, we report on three individual patients who received BTX‐B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX‐B at remote sites. © 2005 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>side effects of botulinum toxin B</term></item><item><term>parasympathetic dysfunction</term></item><item><term>visual system disturbance</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-06-11">Received</change><change when="2004-11-15">Registration</change><change when="2005-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/59E2F4877B7977C1F915CA55E7AB648C4D0EB058/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="70"><doi origin="wiley" registered="yes">10.1002/mds.v20:7</doi><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue">7</numbering></numberingGroup><coverDate startDate="2005-07">July 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="160" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20466</doi><idGroup><id type="unit" value="MDS20466"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2005 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2004-06-11"></event><event type="manuscriptRevised" date="2004-08-25"></event><event type="manuscriptAccepted" date="2004-11-15"></event><event type="publishedOnlineEarlyUnpaginated" date="2005-04-01"></event><event type="firstOnline" date="2005-04-01"></event><event type="publishedOnlineFinalForm" date="2005-07-05"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">877</numbering><numbering type="pageLast">880</numbering></numberingGroup><correspondenceTo>Movement Disorders Center, Department of Neurology, Glenbrook Hospital, Evanston Northwestern Healthcare, 2100 Pfingsten Road, Suite B110, Glenview, IL 60025</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20466.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="12"></count><count type="wordTotal" number="2232"></count></countGroup><titleGroup><title type="main" xml:lang="en">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title><title type="short" xml:lang="en">Visual System Abnormalities with BTX‐B</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Jordan</givenNames><familyName>Dubow</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Angela</givenNames><familyName>Kim</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Jerrold</givenNames><familyName>Leikin</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Kirk</givenNames><familyName>Cumpston</familyName><degrees>DO</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Sean</givenNames><familyName>Bryant</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6" corresponding="yes"><personName><givenNames>Michael</givenNames><familyName>Rezak</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email normalForm="movement-disorders@northwestern.edu">movement‐disorders@northwestern.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Plastic Surgery, Section of Ophthalmology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Omega, Evanston Northwestern Healthcare, Evanston, and University of Illinois at Chicago and Cook County Hospital, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Emergency Medicine, University of New Mexico and New Mexico Poison Center, Albuquerque, New Mexico, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Emergency Medicine, Cook County Hospital, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">side effects of botulinum toxin B</keyword><keyword xml:id="kwd2">parasympathetic dysfunction</keyword><keyword xml:id="kwd3">visual system disturbance</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Botulinum toxin type B (BTX‐B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX‐A) it has off‐label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX‐B has also been shown to be a safe and effective alternative for patients who are resistant to BTX‐A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX‐B use. In this study, we report on three individual patients who received BTX‐B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX‐B at remote sites. © 2005 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Visual System Abnormalities with BTX‐B</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title></titleInfo><name type="personal"><namePart type="given">Jordan</namePart><namePart type="family">Dubow</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Angela</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Plastic Surgery, Section of Ophthalmology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jerrold</namePart><namePart type="family">Leikin</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Omega, Evanston Northwestern Healthcare, Evanston, and University of Illinois at Chicago and Cook County Hospital, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kirk</namePart><namePart type="family">Cumpston</namePart><namePart type="termsOfAddress">DO</namePart><affiliation>Department of Emergency Medicine, University of New Mexico and New Mexico Poison Center, Albuquerque, New Mexico, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sean</namePart><namePart type="family">Bryant</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Emergency Medicine, Cook County Hospital, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael</namePart><namePart type="family">Rezak</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA</affiliation><description>Correspondence: Movement Disorders Center, Department of Neurology, Glenbrook Hospital, Evanston Northwestern Healthcare, 2100 Pfingsten Road, Suite B110, Glenview, IL 60025</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-07</dateIssued><dateCaptured encoding="w3cdtf">2004-06-11</dateCaptured><dateValid encoding="w3cdtf">2004-11-15</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">12</extent><extent unit="words">2232</extent></physicalDescription><abstract lang="en">Botulinum toxin type B (BTX‐B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX‐A) it has off‐label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX‐B has also been shown to be a safe and effective alternative for patients who are resistant to BTX‐A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX‐B use. In this study, we report on three individual patients who received BTX‐B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX‐B at remote sites. © 2005 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>side effects of botulinum toxin B</topic><topic>parasympathetic dysfunction</topic><topic>visual system disturbance</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>7</number></detail><extent unit="pages"><start>877</start><end>880</end><total>3</total></extent></part></relatedItem><identifier type="istex">59E2F4877B7977C1F915CA55E7AB648C4D0EB058</identifier><identifier type="DOI">10.1002/mds.20466</identifier><identifier type="ArticleID">MDS20466</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2005 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002F25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:59E2F4877B7977C1F915CA55E7AB648C4D0EB058
|texte= Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections
}}
| This area was generated with Dilib version V0.6.23. |  |